Description: Shanghai Kaibao Pharmaceutical CO.,Ltd engages in the research, development, production, and sale of modern Chinese medicines primarily in China. Its primary products include Tanreqing injection for the treatment of pneumonia, acute and chronic bronchitis, and upper respiratory tract infection; Tanreqing capsules that clears heat and detoxifies and removes phlegm; tiopronin for injection, which improves liver function of various acute and chronic hepatitis; Tiopronin enteric-coated tablets for adjuvant treatment of chronic hepatitis; and Xiongdan dropping pills that clears heat, calms liver, and improves eyesight. The company was founded in 2000 and is based in Shanghai, China.
Home Page: www.xykb.com
No. 88 Chengpu Road
Shanghai,
201401
China
Phone:
86 21 3757 2030
Officers
| Name | Title |
|---|---|
| Ms. Jingwei Mu | Chairman |
| Mr. Guoming Wang | GM & Director |
| Mr. Yingbin Zhou | Deputy GM & Director |
| Mr. Liwang Ren | Board Sec. |
| Mr. Tao Zhang | Deputy Gen. Mang. |
Exchange: SHE
Country: CN
Currency: Renminbi (¥)
| GIC Sector: | Health Care |
|---|---|
| GIC Group: | Pharmaceuticals, Biotechnology & Life Sciences |
| GIC Industry: | Pharmaceuticals |
| GIC Sub-Industry: | Pharmaceuticals |
| Forward PE: | 0 |
|---|---|
| Trailing PE: | 54.3571 |
| Price-to-Book MRQ: | 2.476 |
| Price-to-Sales TTM: | 12.0717 |
| IPO Date: | 2010-01-08 |
| Fiscal Year End: | December |
| Full Time Employees: | 1432 |